The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial.
 
Masatoshi Kudo
Honoraria - Ajinomoto; Bayer; Eisai; Kaken Pharmaceutical; Otsuka
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Chugai Pharma; Kowa; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kowa (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sceti Medical Labo (Inst); Shizuoka Industry (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Shuichi Kaneko
Honoraria - Ajinomoto; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; GlaxoSmithKline; Mitsubishi Tanabe Pharma; MSD; Otsuka; Taiho Pharmaceutical; Taisho Toyama Pharma; Toray Industries; Zeria Pharmaceutical
Consulting or Advisory Role - Bayer; Chugai Pharma; Kowa; Taiho Pharmaceutical
Research Funding - Abbott Japan (Inst); Abbvie (Inst); ASKA Pharmaceutical (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Janssen (Inst); JIMRO (Inst); Kubix (Inst); Kyorin (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); Novartis (Inst); Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Rohto Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Toray Industries (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Eisai; Fujifilm; GlaxoSmithKline; J-Pharma; Janssen; Kowa; Kyowa Hakko Kirin; Merck Serono; Nobelpharma; OncoTherapy Science; Otsuka; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Madoka Takeuchi
No Relationships to Disclose
 
Xuemin Fang
No Relationships to Disclose
 
Yoshito Date
Consulting or Advisory Role - Hitachi Chemical
 
Masahiro Takeuchi
Honoraria - Mitsubishi Tanabe Pharma; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Hisamitsu Pharmaceutical; Kyorin; Sanofi; Taiho Pharmaceutical